CD8A and non-small cell lung carcinoma: Consequently, immunotherapy alone, or in combination, conferred a greater benefit in cases with KRASG12C mutation, as it is linked to a greater TMB in NSCLC, commonly associated to tobacco-related carcinogenesis [24], as well as more efficient tumor neoantigen presentation to T cells, higher infiltration of CD8+ T cells, and increased PD-L1 expression [5].